Isocarboxazid Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg
Reference Brands: Marplan®(US)
Category:
Antipsychotropic Drugs
Isocarboxazid (Marplan®) is an MAOI used for treatment-resistant depression. Available as 10 mg tablets in the US, it enhances serotonin and norepinephrine levels. While rarely marketed in the EU, it may be available under special access. Find reliable Isocarboxazid suppliers at Pharmatradz.com.
Isocarboxazid Tablets is available in Tablets
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Isocarboxazid Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Isocarboxazid Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Isocarboxazid tablets, a monoamine oxidase inhibitor (MAOI), are FDA-approved in the U.S. for the treatment of depression, particularly in patients who have not responded to other therapies. Due to its potential for serious food and drug interactions, it carries a Boxed Warning for hypertensive crisis and serotonin syndrome. U.S. regulatory requirements include strict labeling, patient safety guides, and GMP-compliant manufacturing. In the European Union, isocarboxazid is either limited or unavailable due to safety concerns, with alternatives preferred. EU dossiers, if present, must include pharmacovigilance protocols and Risk Management Plans (RMPs). Explore sourcing options at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing